Compare Dow Inc (DOW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Twist Bioscience Corp — how do they compare? Dow Inc trades at $30.74 (market cap $22.58B), while Twist Bioscience Corp trades at $123.93 (market cap $7.72B). The key difference: Dow Inc is far larger — about 2.9× Twist Bioscience Corp's market cap, and Dow Inc pays a 4.48% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DOW | TWST | |
|---|---|---|
Market Cap | $22.58B | $7.72B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $124.88 |
52-Week Low | $20.65 | $24.16 |
Enterprise Value | $38.27B | $7.65B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.58, up 4.23% today, with a neutral technical signal and bullish moving averages. Recent earnings have consistently beaten estimates, but the company reported a net loss of -$2.62B in 2025, with declining revenue and negative profit margins. Cash flow from operations improved in 2025 to $1.03B, though debt levels have risen. The stock is trading below the analyst consensus price target of $35.11, with a mixed analyst rating of 33% buy, 53% hold, and 14% sell.
The outlook is cautious; while earnings beats and a dividend payment provide some support, persistent net losses, revenue declines, and rising debt pose significant risks. Investors should weigh the potential for operational turnaround against fundamental weaknesses and macroeconomic pressures on the chemicals sector.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
